Fierce Biotech reports clinical leaders should shift from asking for an an AI strategy to asking three specific questions instead.

For small to mid-sized pharma, CROs, or biotech, this means less high-level talk and more concrete action. Stop chasing buzzwords. The EU AI Act is coming; you need to know *how* AI will solve a specific problem, *who* owns the data, and *what* the ROI looks like. It’s about building a robust, compliant foundation, not just experimenting.